Yanhong Deng

2026

• PTEN deficiency impairs MHC-I-mediated tumour immunity via NRF2-dependent autophagy in microsatellite stable colorectal cancer

  Cai R, Zhan W, Lyu X, Yang X, Wu Z, Cheng Y, Guo C, Feng J, Fu Y, Xie Y, Qin G, Deng Y, Zhang J. PTEN deficiency impairs MHC-I-mediated tumour immunity via NRF2-dependent autophagy in microsatellite stable colorectal cancer. Gut 2026, gutjnl-2026-338195. PMID: 42173678, DOI: 10.1136/gutjnl-2026-338195.

  Peer-Reviewed Original Research

• Neoadjuvant mFOLFOXIRI with or without cadonilimab versus mFOLFOX6 in locally advanced colorectal cancer: A randomized phase 2 trial (OPTICAL-2)

  Zhang J, Qi S, Hu H, He X, Huang L, Zhou J, Wang H, Wu X, Kang L, Huang M, He Z, Wang H, Chen D, Zhai X, Xie X, Ling J, Zhang Y, Hu J, Li S, Wu Z, Yang T, Cai R, Cai Y, Zhong L, Li W, Shi L, Wang C, Huang Y, Zhao Y, Cao W, Qin G, Deng Y. Neoadjuvant mFOLFOXIRI with or without cadonilimab versus mFOLFOX6 in locally advanced colorectal cancer: A randomized phase 2 trial (OPTICAL-2). Med 2026, 7: 101141. PMID: 42134324, DOI: 10.1016/j.medj.2026.101141.

  Peer-Reviewed Original Research

  Citations

  Altmetric

  MeSH Keywords

• Mortality and Infectious Adverse Events in Neutropenic Patients Undergoing Gastrointestinal Endoscopic Procedures: A Systematic Review and Meta-Analysis

  Bahirwani J, Chugh R, Tran A, Ogurick A, Grimshaw A, Ciarleglio M, Deng Y, Al-Bawardy B, Hung K, Laine L. Mortality and Infectious Adverse Events in Neutropenic Patients Undergoing Gastrointestinal Endoscopic Procedures: A Systematic Review and Meta-Analysis. Gastro Hep Advances 2026, 5: 100994. PMID: 42293779, PMCID: PMC13264052, DOI: 10.1016/j.gastha.2026.100994.

  Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus Statements

• Cetuximab plus capecitabine every three weeks as first-line maintenance therapy for RAS/BRAF wild-type metastatic colorectal cancer: a phase Ib dose-escalation study

  Xie X, Lin Z, Li W, Xie Y, Zhang J, Hu H, Li S, Zhai X, Shi L, Deng Y. Cetuximab plus capecitabine every three weeks as first-line maintenance therapy for RAS/BRAF wild-type metastatic colorectal cancer: a phase Ib dose-escalation study. Npj Precision Oncology 2026 PMID: 42032138, DOI: 10.1038/s41698-026-01429-7.

  Peer-Reviewed Original Research

• Validation of the Ectropion Severity Score in Epidermal Differentiation Disorders

  Echeandia-Francis C, Luo A, Jiang X, Ellis K, Mani M, Chen T, Gan G, Deng Y, Choate K. Validation of the Ectropion Severity Score in Epidermal Differentiation Disorders. JAMA Dermatology 2026, 162: 535-537. PMID: 41779411, PMCID: PMC12961595, DOI: 10.1001/jamadermatol.2025.6166.

  Peer-Reviewed Original Research

  Altmetric

• Who Gets Panretinal Photocoagulation? National Patterns in Proliferative Diabetic Retinopathy Treatment

  Applebaum S, Fu J, Bakhoum M, Deng Y, Nwanyanwu K, Consortium S, Amin S, Edwards P, Srikumaran D, Woreta F, Schultz J, Shrivastava A, Ahmad B, Pasquale L, Bryar P, French D, Hribar M, Thomas M, Vanderbeek B, Pershing S, Wang S, Deiner M, Sun C, Patnaik J, Subramanian P, Munir S, Munir W, Stein J, De Lott L, Ramachandran R, Feldman R, Stagg B, Wirostko B, McMillian B, Sheybani A, Sarrafpour S, Harris-Nwanyanwu K. Who Gets Panretinal Photocoagulation? National Patterns in Proliferative Diabetic Retinopathy Treatment. Ophthalmology Science 2026, 6: 101181. PMID: 42125537, PMCID: PMC13158752, DOI: 10.1016/j.xops.2026.101181.

  Peer-Reviewed Original Research

• Distinct molecular and tumor microenvironment characteristics of mucinous adenocarcinoma in colorectal cancer

  Li J, Fu Y, Bai F, Wu Z, Qin G, Deng Y. Distinct molecular and tumor microenvironment characteristics of mucinous adenocarcinoma in colorectal cancer. IScience 2026, 29: 115534. PMID: 42100746, PMCID: PMC13145884, DOI: 10.1016/j.isci.2026.115534.

  Peer-Reviewed Original Research

  Altmetric

• Risk Factors for the Development of Avascular Necrosis Following Hematopoietic Cell Transplantation for Sickle Cell Disease

  Hamidi R, Nallagatla V, Liang J, Deng Y, Flagg A, Shah N, Prior D, Krishnamurti L. Risk Factors for the Development of Avascular Necrosis Following Hematopoietic Cell Transplantation for Sickle Cell Disease. Transplantation And Cellular Therapy 2026, 32: 664.e1-664.e3. PMID: 41905705, DOI: 10.1016/j.jtct.2025.12.1002.

  Peer-Reviewed Original Research

  Altmetric

• Camrelizumab plus CAPOX with camrelizumab based maintenance versus CAPOX alone as initial treatment for gastric or gastro-oesophageal junction adenocarcinoma: randomised phase 3 trial

  Peng Z, Zhang Y, Xu H, Yang Y, Yang M, Zhang M, Cheng Y, Chen X, Pan Y, Wang F, Li Q, Xu N, Liu L, Gu K, Xiao J, Zhang R, Zhao Q, Chen J, Lin L, Chen Y, Deng Y, Cai S, Bai B, Wang Y, Shen L. Camrelizumab plus CAPOX with camrelizumab based maintenance versus CAPOX alone as initial treatment for gastric or gastro-oesophageal junction adenocarcinoma: randomised phase 3 trial. The BMJ 2026, 392: e086115. PMID: 41819560, PMCID: PMC12980530, DOI: 10.1136/bmj-2025-086115.

  Peer-Reviewed Original Research

  Citations

  Altmetric

  MeSH Keywords

• Trastuzumab Rezetecan in Human Epidermal Growth Factor Receptor 2–Expressing Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma and Colorectal Cancer: A Multicenter, Open-Label, Phase I Trial

  Liu T, Luo S, Yuan X, Liu D, Zhou Z, Wang X, Deng Y, Chen J, Liu M, Zhou H, Ren X, Qiu W, Cao Y, Cai S, Dong Y, Zhang Y, Wang W, Liang J, Xu P, Liu H, Zhao K, Fan Y, Dou N, Huang C, Li J. Trastuzumab Rezetecan in Human Epidermal Growth Factor Receptor 2–Expressing Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma and Colorectal Cancer: A Multicenter, Open-Label, Phase I Trial. Journal Of Clinical Oncology 2026, 44: 1225-1237. PMID: 41779980, DOI: 10.1200/jco-25-00716.

  Peer-Reviewed Original Research

  Citations

  Altmetric